Quanterix Corporation Aktie News

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the “Board”) has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective ...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the prestigious journal Nature. The study, which utilized Quanterix's ultra-sensitive Simoa p-Tau 217 (phosphorylated tau at threonine 217) research assay, is the large...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished ...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the publication of a landmark study in the high-impact journal Brain. The paper validates that multiplexed Simoa assays for Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) esta...

Quanterix Corporation ( QTRX ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Joshua Young Masoud Toloue - President, CEO & Director Vandana Sriram - CFO & Treasurer Conference Call Participants Kyle Mikson - Canaccord Genuity Corp., Research Division Daniel Brennan - TD Cowen, Research Division Puneet Souda - Leerink Partners LLC, Research Division Tom DeBourcy - Neph...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the third quarter ended September 30, 2025. “During the third quarter, we delivered on our revenue expectations despite challenging market conditions,” said Masoud Toloue, Chief Exe...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, November 10, 2025, at 4:30 p.m. E.T., to discuss its third quarter 2025 financial results. Quanterix will issue a press release regarding its third quarter 2025 financial results...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by...